Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Inhibitors & Agonists > Others > Other Targets

Other Targets

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC8143 RBC8 Featured
RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell.
More description
DC11392 SEC inhibitor KL-2 Featured
SEC inhibitor KL-2 is a peptidomimetic inhibitor of super elongation complex (SEC) and transcription elongation by Pol II, disrupts cyclin T1-AFF4 interaction (Ki=1.50 uM) within SEC; disrupts the interaction between the SEC scaffolding protein AFF4 and P
More description
DC11391 SEC inhibitor KL-1 Featured
SEC inhibitor KL-1 is a peptidomimetic inhibitor of super elongation complex (SEC) and transcription elongation by Pol II, disrupts cyclin T1-AFF4 interaction (Ki=3.48 uM) within SEC; disrupts the interaction between the SEC scaffolding protein AFF4 and P
More description
DC22635 SPDP Featured
SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker u
More description
DC34338 Pyrintegrin Featured
Pyrintegrin is a cell-permeable promoter of the adhesion of individually dissociated hESCs on matrigel- or laminin-, but not gelatin-coated surfaces, substantially reducing trypsinization-induced apoptosis.
More description
DC7223 Palomid 529 (P529) Featured
Palomid 529 (P529) is a novel potent inhibitor of both the mTORC1 and mTORC2 complexes with a GI50 of <35 μM in the NCI-60 cell lines panel; reduces phosphorylation of pAktS473, pGSK3βS9, and pS6 but no effect observed on pMAPK or pAktT308.
More description
DCAPI1391 Ranolazine (Ranexa) Featured
Ranolazine (Ranexa)
More description
DC10899 Ralinepag Featured
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
More description
DC8011 Radotinib (IY-5511) Featured
Radotinib(IY-5511) is a novel and selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM for wild-type BCR-ABL1 kinase.
More description
DC9103 Rebeprazole sodium
Rabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors.
More description
DC7258 Bemcentinib(R428,BGB324) Featured
R428 is a potent and selective small-molecule inhibitor(IC50=14 nM), blocks the activities of Axl.
More description
DC10692 R162 Featured
R162 is an inhibitor of GDH activity and represses glioma cell growth.
More description
DC7206 R1530 Featured
R1530 is the multikinase inhibitor with potential antiangiogenesis and antineoplastic activities.
More description
DC8657 R112 Featured
R112 is an ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM. R112 inhibits Syk kinase activity with an IC50 of 226 nM.
More description
DC23125 Pyrotinib maleate Featured
Pyrotinib maleate (SHR-1258 maleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively.
More description
DC20241 PIH(Pyridoxal isonicotinoyl hydrazine) Featured
Pyridoxal isonicotinoyl hydrazine is a lipophilic, nontoxic, iron-chelating agent that shows high iron chelation efficacy both in vitro in cell culture models and in vivo in rats and mice.
More description
DC8091 Pyridostatin trifluoroacetate salt Featured
Pyridostatin stabilizes G-quadruplexes, targeting the proto-oncogene SRC and telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest.
More description
DC7992 PX 12 Featured
PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1(Trx-1) currently in clinical development as an antitumor agent; IC50=7 uM in Hela, MTT assay, 72 h.
More description
DC8495 PTC-209 hydrobromide Featured
PTC-209 is a specific inhibitor for BMI-1 with IC50 of 0.5 uM in in both GEMS reporter and ELISA assays.
More description
DC7485 PTC-209 Featured
PTC-209 is a specific inhibitor for BMI-1 with IC50 of 0.5 uM in in both GEMS reporter and ELISA assays.
More description
DC2005 PTC124 (Ataluren) Featured
PTC124 (Ataluren) is a potent nonsense mutation inhibitor with EC50 of ~0.1 μM.
More description
DC6308 Sofosbuvir(PSI7977,GS-7977) Featured
PSI-7977 is an investigational nucleotide analog currently in Phase 2 for treatment of chronic HCV infection.
More description
DC10397 Proguanil Featured
Proguanil is an antimalarial prodrug that is metabolized to the active metabolite cycloguanil, a dihydrofolate reductase (DHFR) inhibitor.
More description
DC7252 PR-619 Featured
PR-619 is a broad-range DUB inhibitor with potential for further development as a chemotherapeutic agent in cancer therapy.
More description
DC5008 PP2(AGL 1879) Featured
PP2 is Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
More description
DC9931 PP2 analog Featured
PP2 analog is the analog of PP2,a Src family kinase inhibitor.
More description
DC5007 pp1 Featured
PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
More description
DC7239 PluriSln 1(NSC 14613) Featured
PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
More description
DC8749 Plinabulin Featured
Plinabulin (NPI-2358) is a vascular disrupting agents (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells.
More description
DC10821 PKG drug G1 Featured
PKG drug G1 has been shown to induce the oxidative activation of protein kinase G Iα, which in vivo results in dilation of blood vessel and blood pressure lowering; an antihypertensive.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X